Action in Fokus: Bayer – Gelingt der Ausbruch dann eröffnet sich Aufwärtspotenzial bis zum Jahreshoch

one markets: Bayer Leverkusen goes to the Champions League and has won its first match.

The sponsorship of the Deutschen Meisters sponsorship is allemählich Früchte.

During the period in which the Life Science activities are taking place, investments in the pharmaceutical sector are all good for the future.

Den Anlegern dies no more.

The Leverkusener-konzern is primarily in three major areas: Crop Science with Dungemittel and Pestizides, Pharmaceuticals with health care products as well as Consumer Healthcare with available medicines.

Der Crop Science-Bereich steuerte im ersten Halbjahr 2024 über 51 Prozent zum Gesamtumsatz bei.

The Pharma sector generates 36 products and consumer healthcare on 11 products from Konzernumsatzes.

Die Margen lie jeweils oberhalb von 20 Prozent.

Dennoch is active in the years under Druck.

2026 put the Glyphosat-Klagen into use

A greater burden factor is the suspension of the Glyphosat-Klagen which has produced an angeblich krebserregenender effect of the impure vernichters.

In the Zurückliegenden Wochen, Bayer won a Reihe von Klagen.

Youngest Messages are expected to be 2/3 deleted or deleted from the Vergleichskriterien.

Round 58,000 Complaints since Konzernangaben zufolge jedoch noch offen. There are even more Milliardenzahlungen.

“In 2026, Bayer will die from the Glyphosat-Klagen significantly endämmen, so Bill Anderson will deal with all Kraft,” said Matthias Berninger, chief lobbyist of the Konzerns, informed the “Rheinische Post”.

If you die, Bayer will make a new start for the Supreme Court of the American car.

Increase milder temperatures and Bayer’s recommended pressure during that time. Segment im ersten Halbjahr-reports van een reversal van de drei Prozent Hinnehmen.

Gleichwohl will bring Bayer to the market in the Diesem Segment in the coming 10 years and 10 Blockbuster.

So Bayer waits for other people with a new Herbizid Icafolin for Ackerkulturen.

With the Preceon Smart Corn System, Bayer will revolutionize Maisanbau.

Preceon-Pflanzen are no longer and therefore wider standsfähiger gegenüber strong winds and flowy wet conditions.

2 potential Blockbusters in the Pipeline

Anderson’s big business is the product pipeline in the pharmaceutical sector.

Be a Top Seller

The Augenmittel effect will be a lighter addition, after the patent on the Blockbuster drugs has delivered in recent years.

With the summary of the young research into the Gerinnungsmittel Asundexian, the Pipeline can erlitten a herben Rückschlag.

Daher used Anderson for everything on Nubeqa and Kerendia.

The current prostate drug drug has been active in the United States and Europe through 2024, gaining 78 percent of previous years.

Pursuing new studies offers the chance of having a sister for further support. Analogue Plane hat Bayer with the Herz- and Kidney medication Kerendia (Fenerenon).

Kerendia protected the Bayer-Konzern in Halbjahr a Umsatzzuwachs von rund 70 Prozent.

Make sure that you can make the deliveries on a new Fachkonferenz date.

A Zulassung zur Behandlung von Herzinsuffizienz kan de Umsatz in de Hoge Schnellen Lassen.

They both have a Hoffnungsträgern setzt from the Konzernchef for everything regarding Elinzanetant zur Behandlung von Wechseljahrbeschwerden.

A Zulassung in the US is attractive. With a Zulassung met Mitte 2025 gechnet.

Darüberhinaus has worked with Bayer for a number of years on other Genetherapie-Entwickler Asklepios BioPharmaceutical, the Zelltherapie-Entwickler BlueRock Therapeutics and Vividion Therapeutics, the chemoproteomics platform for drug treatment for credit and immunotherapy names, the Pipeline is strong.

If your market forces are a drug, this is less than a year ago.

Umbau is coming soon

High debts and teure processes burden the work. However Anderson does it, it takes a lot of effort to cut costs.

The management and labor process will be reduced and will be reduced until 2026. The cost of a beef will be two billion euros.

A larger part will go through the couples’ stretches.

At the Vorlage of the Halbjahreszahlen, Anderson is in Plan.

The fact is that the rule of law has put an end to an engagement agreement.

The KGV of 5 said that the certain risk has been taken into account.

Weitere Rückschläge since yet not released.

Bayer Action Chart

Bayer Action Chart Analysis

• Wider market prices: 29.65/32.50/36.00EUR
• Understützungsmarken: EUR 18.70/25.40

Bayer’s action announced an Abwärts trend during the 2017 quarter.

Since February, the paper costs between EUR 25.40 and EUR 29.65.

The most recent RSI indicator is neutral. The most recent MACD indicator works afterward.

Aktuell notes de Aktie an der Oberkante der Bandbreite.

Gelingt der Ausbruch über EUR 29,65 eröffnet sich morees Aufwärtspotenzial bis zum Jahreshoch von EUR 36.

Neither is it jedoch nor nothing anyway. Be sure to eat some muss with a few more pieces of meat.

Kippt the promotion for an amount of EUR 25.40 and a further sale up to EUR 18.70.

Bayer in EUR

Bayer in EUR